These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A recombinant tumor necrosis factor-alpha p80 receptor:Fc fusion protein decreases circulating bioactive tumor necrosis factor-alpha but not lung injury or mortality during immunosuppression-related gram-negative bacteremia.
    Author: Lechner AJ, Johanns CA, Matuschak GM.
    Journal: J Crit Care; 1997 Mar; 12(1):28-38. PubMed ID: 9075062.
    Abstract:
    PURPOSE: During gram-negative bacteremia (GNB), tumor necrosis factor-alpha (TNF-alpha) is a critical early mediator of host defense, whose overexpression can initiate acute lung injury, multiple organ failure, and death. In this study we evaluated the ability of a chimeric fusion protein containing two extracellular domains of the human p80 TNF-alpha receptor and the Fc region of human IgG1 (TNFR:Fc) to reduce circulating TNF-alpha, and to ameliorate organ injury and improve survival in a rodent model of GNB during immunosuppression-related neutropenia. MATERIALS AND METHODS: Conscious catheterized male rats (n = 37) with stable cyclophosphamide-induced neutropenia were infected intravenously (i.v.) with 5 x 10(9) live Escherichia coli (EC, serotype O55:B5) ending at t = 0. All animals received antibiotics (penicillin/ amikacin sulfate) at t = 0.5 and t = 8 hours, and 0.9% sodium chloride (normal saline solution (NS), 1 mL/h) from t = 0 to 8 hours. Subgroups were post-treated at t = 0.5 hours with a 1.0 mL i.v. dose of TNFR:Fc (60, 600, or 1,200 micrograms; Immunex), 600 micrograms of human IgG1-kappa or IgG1-lambda (Sigma), or NS alone (controls). A separate TNFR:Fc pretreatment subgroup received 600 micrograms/rat of the fusion protein 5 minutes before starting EC infusion. Hemodynamics were monitored continuously through t = 24 hours, and arterial samples were collected at baseline and at t = 1.5, 4.5, 8, and 24 hours after EC were analyzed for blood gases, quantitative culture, serum endotoxin, bioactive and antigenic TNF-alpha, and formed elements. Postmortem tissues were examined for histopathologic changes. RESULTS: Compared with antibiotic-treated and fluid-supported controls, TNFR:Fc dose-dependently reduced bioactive but not antigenic TNF-alpha without altering bacterial clearance, serum endotoxin, or 24-hour survival. Of note, 600 micrograms of IgG1-kappa or IgG1-lambda attenuated peak bioactive TNF-alpha to a similar degree as 1,200 micrograms TNFR:Fc, and also significantly reduced serum endotoxin levels. Nevertheless, by t = 8 hours all bacteremic rats were hypothermic with tachypnea-related hypocarbia and hyperoxemia and were thrombocytopenic. At death, all subgroups showed similar hepatic glycogen depletion and pulmonary congestion with perivascular edema and alveolar hemorrhage. CONCLUSIONS: Although TNFR:Fc and its idiotypic control IgG1 reduced circulating bioactive TNF-alpha, neither treatment prevented progression of lethal shock with attendant organ injury in this conscious, antibiotic-treated and fluid-resuscitated model of immunosuppression-related GNB.
    [Abstract] [Full Text] [Related] [New Search]